Jorgensen R - Search Results

1

Reliability and validity of the NIDDK-QA instrument in the assessment of quality of life in ambulatory patients with cholestatic liver disease.

Kim WR, Lindor KD, Malinchoc M, Petz JL, Jorgensen R, Dickson ER. Kim WR, et al. Among authors: jorgensen r. Hepatology. 2000 Nov;32(5):924-9. doi: 10.1053/jhep.2000.19067. Hepatology. 2000. PMID: 11050040

2

The predictors of the presence of varices in patients with primary sclerosing cholangitis.

Treeprasertsuk S, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, Harnois D, Jorgensen R, Petz J, Keach J, Schmoll J, Hoskin T, Thapa P, Enders F, Lindor KD. Treeprasertsuk S, et al. Among authors: jorgensen r. Hepatology. 2010 Apr;51(4):1302-10. doi: 10.1002/hep.23432. Hepatology. 2010. PMID: 20044810 Free PMC article. Clinical Trial.

3

The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: the results of a pilot study.

Lindor KD, Dickson ER, Jorgensen RA, Anderson ML, Wiesner RH, Gores GJ, Lange SM, Rossi SS, Hofmann AF, Baldus WP. Lindor KD, et al. Among authors: jorgensen ra. Hepatology. 1995 Oct;22(4 Pt 1):1158-62. doi: 10.1016/0270-9139(95)90624-x. Hepatology. 1995. PMID: 7557866 Clinical Trial.

4

Bone disease in primary biliary cirrhosis: does ursodeoxycholic acid make a difference?

Lindor KD, Janes CH, Crippin JS, Jorgensen RA, Dickson ER. Lindor KD, et al. Among authors: jorgensen ra. Hepatology. 1995 Feb;21(2):389-92. Hepatology. 1995. PMID: 7843710 Clinical Trial.

5

Does antimitochondrial antibody status affect response to treatment in patients with primary biliary cirrhosis? Outcomes of ursodeoxycholic acid therapy and liver transplantation.

Kim WR, Poterucha JJ, Jorgensen RA, Batts KP, Homburger HA, Dickson ER, Krom RA, Wiesner RH, Lindor KD. Kim WR, et al. Among authors: jorgensen ra. Hepatology. 1997 Jul;26(1):22-6. doi: 10.1002/hep.510260103. Hepatology. 1997. PMID: 9214447 Clinical Trial.

6

Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis.

Angulo P, Batts KP, Therneau TM, Jorgensen RA, Dickson ER, Lindor KD. Angulo P, et al. Among authors: jorgensen ra. Hepatology. 1999 Mar;29(3):644-7. doi: 10.1002/hep.510290301. Hepatology. 1999. PMID: 10051462 Clinical Trial.

7

Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial.

Angulo P, Dickson ER, Therneau TM, Jorgensen RA, Smith C, DeSotel CK, Lange SM, Anderson ML, Mahoney DW, Lindor KD. Angulo P, et al. Among authors: jorgensen ra. J Hepatol. 1999 May;30(5):830-5. doi: 10.1016/s0168-8278(99)80136-6. J Hepatol. 1999. PMID: 10365809 Clinical Trial.

8

Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid.

Angulo P, Jorgensen RA, Keach JC, Dickson ER, Smith C, Lindor KD. Angulo P, et al. Among authors: jorgensen ra. Hepatology. 2000 Feb;31(2):318-23. doi: 10.1002/hep.510310209. Hepatology. 2000. PMID: 10655252

9

Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid.

Angulo P, Patel T, Jorgensen RA, Therneau TM, Lindor KD. Angulo P, et al. Among authors: jorgensen ra. Hepatology. 2000 Nov;32(5):897-900. doi: 10.1053/jhep.2000.18663. Hepatology. 2000. PMID: 11050036 Clinical Trial.

10

Etidronate for osteoporosis in primary biliary cirrhosis: a randomized trial.

Lindor KD, Jorgensen RA, Tiegs RD, Khosla S, Dickson ER. Lindor KD, et al. Among authors: jorgensen ra. J Hepatol. 2000 Dec;33(6):878-82. doi: 10.1016/s0168-8278(00)80118-x. J Hepatol. 2000. PMID: 11131448 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

572 results

Search Page

Filters